Who We Serve · Wellness products
What does a peptide clinic need to stay compliant?
Where a clinic may lawfully source peptides, how the practice should be structured, what consent and patient data handling require, and what a compliance audit covers.
01 The short answer
Source, structure, consent and data.
Four things decide exposure: where the peptides are sourced and under which compounding pathway, whether the corporate structure respects the corporate-practice-of-medicine rules in your state, whether informed consent reflects what is actually being prescribed, and whether patient data handling meets HIPAA.
- Lawful sources
- 503A or 503BLicensed pharmacy or outsourcing facility
- Areas of exposure
- FiveSourcing, structure, consent, data, marketing
- Physician equity
- 100%Of the professional entity, as the source describes
- Consent refresh
- At least yearlyAnd on any protocol or status change
02 The exposure
Five areas, one enforcement priority.
Five areas carry the exposure: where the peptides come from, how the practice is structured, what informed consent says, how patient data is handled, and how the clinic markets itself.
Regulators have treated peptide clinics as an enforcement priority. The source counts more than 50 FDA warning letters since late 2024, state medical board investigations in Ohio, California and other states, and a signal from the Department of Justice that criminal charges may follow against certain industry participants. One clinic can face a federal referral, a state attorney general action, board discipline and malpractice claims from the same failures.
For where BPC-157 specifically stands, see BPC-157 legal status in 2026.
03 Sourcing
Sourcing decides whether the operation is lawful.
| Source | Lawful? |
|---|---|
| Licensed 503A compounding pharmacy filling a patient-specific prescription | Yes, under Section 503A of the Federal Food, Drug, and Cosmetic Act |
| Licensed 503B outsourcing facility, which makes compounded drugs without individual prescriptions under heightened FDA oversight | Yes |
| Overseas manufacturer, online research-use-only (RUO) vendor, any supplier that is not an FDA-registered facility, or any source shipping product labeled "not for human consumption" or "research use only" when the intended use is clinical | No |
03 Sourcing · continued
An RUO disclaimer gives no legal cover. If the marketing, packaging, distribution channel or end use shows the product is meant for human administration, the FDA treats it as misbranding and distributing an unapproved new drug.
| Class | What it means |
|---|---|
| Category 1 | On the FDA's positive Bulks List; a 503A pharmacy can compound it on a valid patient-specific prescription. The source gives Sermorelin as an example |
| Category 2 | Designated as raising significant safety concerns. As of April 2026 several, BPC-157 among them, have been removed, but removal does not authorize compounding until the advisory committee review and formal rulemaking are complete |
03 Sourcing · continued
| Class | What it means |
|---|---|
| Unclassified | Never reviewed by the FDA and on no list; the highest risk, with no established legal pathway to compound it for clinical use |
Every peptide in your formulary needs a documented compliance assessment against its current FDA status, repeated as the rules move. Your contracts with compounding pharmacies should say what happens when a classification changes.
04 Structure
Physician control, on paper and in practice.
Corporate practice of medicine (CPOM) laws exist in most states to keep medical decisions with licensed physicians rather than corporations or non-clinical owners. Regulators of peptide clinics look closely at whether non-physician owners or management companies are steering which peptides are prescribed, at what dose and from which source.
Clinics with non-physician investors usually use a Management Services Organization (MSO) model: a Professional Corporation (PC) or Professional Limited Liability Company (PLLC) owned by the physician, and an MSO that handles marketing, billing, HR and facilities. The structure works only if the physician keeps full control of clinical decisions in both the paperwork and daily operations.
04 Structure · continued
The source describes the 2026 standard as the end of the paper MSO: regulators compare the management agreement with the bank statements, emails, hiring logs and operating records. A defensible structure, as the source describes it, has these features:
- the physician owner holds 100% equity in the professional entity
- procurement of pharmaceutical products stays under the physician's direct control
- clinical protocols and formulary choices are documented as the physician's independent medical judgment
- the MSO does not run sweep accounts that automatically move patient payments into its own account
- the physician has final authority over the practice's funds and authorizes payment of clinical staff and purchases of medical supplies
If your structure falls short, restructure before a regulator looks at it. See entity structuring for how the pieces fit.
05 Consent
Beyond a standard treatment form.
Consent for compounded, non-FDA-approved peptides must go beyond a standard form:
- the peptide name, source (compounding pharmacy name and license number), lot number, route of administration and dosage
- a clear statement that the peptide is not FDA-approved for any indication and has not completed human clinical trials
- expected benefits and known risks, including allergic reactions, infection at the injection site and unknown long-term effects
- the alternative therapies considered
- the documented medical indication behind the prescription
Consent must be written, patient-signed and kept in the medical record; refresh it on protocol or regulatory status changes and at least annually for ongoing therapy.
Each file also needs the medical indication and clinical rationale, baseline and follow-up labs as clinically appropriate, response monitoring and adverse event reports: your evidence of the standard of care in a board investigation or malpractice claim.
06 Data and claims
Patient data, state rules and what you may claim.
HIPAA
Dose logs with patient names, lab results, wellbeing scores, injection site records, before-and-after photos and treatment protocols are all protected health information (PHI). Any digital channel that touches PHI needs HIPAA-compliant infrastructure.
A common failure is talking to patients over consumer messaging, such as SMS, WhatsApp or Instagram DMs. Those platforms do not meet HIPAA unless you have signed a Business Associate Agreement (BAA) with the platform and it offers a HIPAA-compliant configuration. Patient management software, electronic health records, scheduling systems and payment processors must be HIPAA-compliant too, and your privacy policy must describe accurately how patient data is collected, stored, shared and protected. A telehealth program has to meet the HIPAA Security Rule's technical safeguards, which many consumer video tools adopted during the pandemic do not.
06 Data and claims · continued
State rules
Every state sets its own rules for prescribing compounded medications. Check these in each state where you operate or see patients:
- which provider types may prescribe compounded peptides
- supervision requirements for nurse practitioners and physician assistants
- telemedicine prescribing rules, especially for first consultations
- mandatory adverse event reporting
For telemedicine across state lines, the prescriber must be licensed in the patient's state and the compounding pharmacy must be licensed to ship into it.
Advertising
Marketing is regulated by the FDA and the FTC. A claim that a peptide treats, cures or prevents a disease or condition is a drug claim that needs FDA approval, so therapeutic claims on a website or social media invite enforcement. State medical boards also regulate physician advertising of outcomes, testimonials and before-and-after images, sometimes more strictly than federal law.
07 The audit
Compliance is not a one-time project.
What a compliance audit should cover
- Sourcing: every supplier verified as FDA-registered and properly licensed
- Structure: the MSO-PC separation documented and actually followed
- Informed consent: current, complete and signed for every active patient
- HIPAA: every system, platform and communication channel checked
- State licensing: provider licenses, facility registrations and pharmacy relationships all current
- Marketing: every claim reviewed against FDA and FTC rules
- Documentation: treatment records complete and defensible
Assign an officer or outside counsel to track FDA classification changes and enforcement actions, state board bulletins, compounding pharmacy rule changes and CPOM enforcement standards. Protect proprietary protocols and patient databases with non-disclosure agreements for staff and vendors; our contracts overview lists the agreements involved.
07 The audit · continued
The failures that most often trigger enforcement
- Unlicensed vendors. Buying from online RUO vendors or overseas manufacturers is the most common failure and the most likely to draw federal action.
- Missing or thin consent. Forms that omit the non-approved status, the compounded nature of the product or the lack of human trial data.
- Paper MSOs. Agreements that claim physician independence while operations show the MSO controlling clinical decisions.
- HIPAA violations. Non-compliant channels, consumer software without BAAs, missing security safeguards.
- Therapeutic claims in marketing. Content saying peptides treat or cure conditions without FDA approval.
08 When this needs a lawyer
Before a regulator looks first.
- You are opening a peptide practice — or adding peptide therapy.
- You are setting up or revising an MSO-PC structure — so the physician's control holds in practice as well as on paper.
- You are qualifying a pharmacy or other supplier — since sourcing decides whether the operation is lawful.
- You are writing consent forms or marketing copy — for peptide therapies.
- A regulator, board or the FDA has contacted you — bring in an attorney who knows FDA regulatory law, state medical practice acts and the corporate practice of medicine. We serve as fractional general counsel for highly regulated businesses.
This is general information, not legal advice. It describes peptide clinic compliance in general terms and cannot account for your clinic, your facts or your state. Reading it does not create an attorney–client relationship.
In clients’ words
What clients say.
- ★★★★★Google
“I hired Next Era Legal to assist with my law firm's corporate incorporation and state bar application, and I couldn't be more pleased with the experience. They completed all paperwork promptly and accurately, and their communication…”
Sally ReddySan Diego Review - ★★★★★Google
“I cannot recommend Eric highly enough! After a disappointing experience with another attorney, we met with Eric for a second opinion—and we were absolutely blown away. His professionalism, expertise, and efficiency made the entire process…”
April AyyoubiSan Diego Review - ★★★★★Google
“As a benefits provider to businesses across San Diego, I'm always on the hunt for trusted advisors to connect with my clients and network. Once I met the team at Next Era Legal, I knew I'd found the right fit. They don't just respond…”
Anthony AnselmoSan Diego Review - ★★★★★Google
“Jeff made a complicated process simple! He looked out for our interests, worked diligently with our other professionals and there were no surprises when it mattered! Thanks, Ted & Hortencia!”
Ted BendrickSan Diego Review - ★★★★★Google
“Could not recommend working with Eric Proos enough! He's thoughtful, responsive, and knowledgeable. He shows a true passion for helping his clients no matter how challenging the circumstances, and is a true professional.”
Sarah PatelSan Diego Review - ★★★★★Google
“Eric and his team were extremely knowledgable and efficient. I'll be using them for many years to come!”
Josh SchwartzSan Diego Review - ★★★★★Google
“can't recommend Eric and his team highly enough! As a small business owner, I had a lot of questions and concerns, and Eric was incredibly knowledgeable, patient, and thorough every step of the way. He helped me feel confident navigating…”
Chelsea WolfeLos Angeles Review - ★★★★★Google
“I have known Atty Jeff Monahan through a professional networking group. He is extremely knowledgeable and easy to talk to. I have consulted with him in several occasions regarding my businesses and I have known several other people who have consulted with him and rave about him as well. I highly recommend his services.”
Shohreh JanfazaLos Angeles Review
Further reading
More on regulatory compliance.
09 People also ask
Questions about peptide clinic compliance.
- 01
Is an RUO label a defense if I give a peptide to a patient?
No.
An RUO (research use only) label is no defense when a peptide is given to a patient. If the marketing, packaging, distribution channel or end use shows the product is meant for human administration, the FDA treats it as misbranded and as an unapproved new drug, which is why buying from RUO vendors heads Next Era Legal's list of common compliance failures.
- 02
Does the physician have to own the clinic?
In an MSO-PC model, the physician owns the professional entity.
Physician ownership of the professional entity is the core of an MSO-PC model: the physician owner holds 100% equity in the PC or PLLC, as the page's source describes it, and keeps control of clinical and financial decisions, while the MSO handles marketing, billing, HR and facilities. State rules differ, so Eric Proos of Next Era Legal advises confirming the rules in your state.
- 03
Is a checkbox consent form enough?
No.
Checkbox-only consent forms, like verbal discussions, do not survive state medical board investigations, by the source's account. Consent has to be written, signed by the patient and kept in the medical record, and the form Next Era Legal describes the peptide's source, states that it is not FDA-approved, and covers its risks, the alternatives and the medical indication.
- 04
Can we text patients about their treatment?
Only through a platform covered by a signed BAA.
Texting patients about treatment is allowed only through a platform covered by a signed Business Associate Agreement and set up for HIPAA compliance. Consumer channels such as SMS, WhatsApp or Instagram DMs do not meet HIPAA on their own, and Next Era Legal lists non-compliant channels among the HIPAA failures it warns clinics about.



Los Angeles
Orange County
San Diego
San Francisco
Houston
Metro Detroit
Washington, DC
Miami